| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| KIG MANAGEMENT | 9,552 | 4,776 | 4,776 |
| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| UNRELATED BUSINESS INCOME SHORT-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 77 | COST | 0 | 77 | |||||
| UNRELATED BUSINESS INCOME SHORT-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 7 | COST | 0 | -7 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | CONTRIBUTIONS TOTALING $947,500 WERE MADE BETWEEN JULY 1, 2020 AND JUNE 30, 2021 TO A DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731; WITH $947,500 BEING DISTRIBUTED IN THE SAME FISCAL YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID (STATEMENT #16). THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE HUGH AND CHARLOTTE MACLELLAN CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| ATLANTA CATHETER THERAPIES | 58,620 | 33,223 |
| NXPHASE | 8,110 | 8,110 |
| NXTHERA | 0 | 63,000 |
| VERAN MEDICAL TECHNOLOGIES | 0 | 133,931 |
| UBS 5434 | 1,045,802 | 1,047,223 |
| UBS 5653 | 795,101 | 795,343 |
| UBS 5654 | 1,044,472 | 1,099,870 |
| UBS 5655 | 536,361 | 507,989 |
| UBS 5656 | 1,539,220 | 1,707,230 |
| UBS 5657 | 771,419 | 811,672 |
| UBS 5658 | 2,480,923 | 2,744,144 |
| UBS 5659 | 628,555 | 640,335 |
| UBS 5817 | 1,561,113 | 1,710,228 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AERIAL BIOPHARMA, LLC | AT COST | 1,487,966 | 5,055 |
| ARRIVO BIOVENTURES, LLC | AT COST | 458,850 | 550,031 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 223,815 | 215,887 |
| C-III RECOVERY FUND II LP | AT COST | 252,716 | 444,926 |
| CEVIAN CAPITAL II, LP | AT COST | 392,936 | 773,610 |
| DYNAMO FUND I, LP | AT COST | 400,241 | 1,746,346 |
| DYNAMO FUND II, LP | AT COST | 160,736 | 195,000 |
| DYNAMO-GATIK LLC | AT COST | 45,463 | 45,463 |
| DYNAMO-SKUPOS, LLC | AT COST | 59,707 | 60,000 |
| DYNAMO-STORD SPV II, LLC | AT COST | 101,033 | 219,588 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 0 | 424,240 |
| GCM GROSVENOR MACLELLAN INVESTMENT FUND LP | AT COST | 42,438 | 65,345 |
| GOODWATER CAPITAL IV L.P. | AT COST | 13,750 | 13,750 |
| H20EY | AT COST | 210,561 | 212,529 |
| KERN CAPITAL LLC | AT COST | 100,000 | 100,000 |
| KERN GENOMIC LLC | AT COST | 100,000 | 100,000 |
| KERN ODYSSEUS LLC | AT COST | 100,000 | 100,000 |
| KNOBB BIOSCIENCES LLC | AT COST | 366,409 | 500,000 |
| IR B FUND, A SERIES OF PATHBREAKER SPV, LP | AT COST | 100,185 | 100,186 |
| MIDNIGHT PHARMA, LLC | AT COST | 15,080 | 55,590 |
| NEXGEN VENTURES FUND II, LP | AT COST | 137,560 | 162,459 |
| NORTH AVENUE CAPITAL, LLC | AT COST | 468,000 | 500,000 |
| ONO FOOD CO. | AT COST | 100,638 | 100,000 |
| PATHBREAKER VENTURES FUND II LP | AT COST | 187,177 | 179,745 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 642,751 | 958,213 |
| RA CAPITAL HEALTHCARE FUND, LP | AT COST | 421,221 | 399,273 |
| RELEVANCE CAPITAL III LP | AT COST | 456,320 | 998,351 |
| RESOLUTE CAPITAL PARTNERS FUND IV, L.P. | AT COST | 729,317 | 1,015,498 |
| RESOURCE LAND FUND, III, LLC | AT COST | 120,079 | 130,509 |
| RIVER VI, L.P. | AT COST | 0 | 151,922 |
| RIVER VII | AT COST | 651,867 | 851,963 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 193,971 | 224,488 |
| SIMBE ROBOTICS | AT COST | 100,250 | 100,250 |
| TENTH STREET FINANCIAL OPPORTUNITY FUND II, L.P. | AT COST | 9,337 | 30,833 |
| TORIC LABS SPV SERIES A | AT COST | 100,970 | 100,970 |
| VALOR OPPORTUNITY FUND I LP | AT COST | 328,961 | 354,367 |
| VALOR VENTURE FUND II LP | AT COST | 815,757 | 2,279,733 |
| VALOR VENTURE FUND III, L.P. | AT COST | 308,879 | 596,206 |
| GOLUB PARTNERS INTERNATIONAL | AT COST | 1,383,665 | 1,810,148 |
| HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS OFFSHORE LP | AT COST | 380,714 | 4,332 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| INVESTMENTS RECEIVABLE | 6,304 | 6,304 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| MANAGEMENT FEES THROUGH BROKERS | 49,037 | 49,037 | 0 | |
| PORTFOLIO DEDUCTIONS THROUGH PARTNERSHIPS | 14,046 | 14,046 | 0 | |
| INVESTMENT INTEREST THROUGH PARTNERSHIPS | 76,608 | 76,608 | 0 | |
| OTHER PARTNERSHIP DEDUCTIONS | 278,162 | 278,162 | 0 | |
| NON DEDUCTIBLE EXPENSES THROUGH PARTNERSHIPS | 26,212 | 0 | 0 | |
| OTHER PARTNERSHIP MANAGEMENT FEES | 579 | 579 | 0 | |
| OFFICE EXPENSE REIMBURSEMENTS | 24,039 | 0 | 24,039 | |
| BANK CHARGE & WIRE FEE | 1,291 | 968 | 323 | |
| SECTION 965(C) DEDUCTION | 2 | 2 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| PARTNERSHIPS ROYALTIES | 15 | 15 | 15 |
| OTHER MISC INCOME | 551 | 551 | 551 |
| UNRELATED BUSINESS INCOME | -183,306 | 0 | -183,306 |
| PARTNERSHIPS OTHER PORTFOLIO INC | -74,491 | -74,491 | -74,491 |
| PARTNERSHIPS OTHER INCOME | -21,244 | -21,244 | -21,244 |
| PARTNERSHIPS ORDINARY INCOME | -3,214 | -3,214 | -3,214 |
| SECTION 965(A) INCOME INCLUSION | 3 | 3 | 3 |
| Description | Beginning of Year - Book Value | End of Year - Book Value |
|---|---|---|
| EARLY DISTRIBUTIONS | 0 | 240,380 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX WITHHELD FROM INCOME | 4,032 | 4,032 | 0 | |
| FOREIGN TAX WITHHELD THROUGH PARTNERSHIPS | 7,641 | 7,641 | 0 | |
| FEDERAL AND STATE EXCISE TAX | 50 | 0 | 0 | |
| STATE TAX WITHHELD FROM PARTNERSHIP INCOME | 1,441 | 1,441 | 0 |